Skip to main content
EMBO Reports logoLink to EMBO Reports
. 2021 Feb 23;22(4):e51749. doi: 10.15252/embr.202051749

Insert L1 is a central hub for allosteric regulation of USP1 activity

Shreya Dharadhar 1, Willem J van Dijk 1, Serge Scheffers 1, Alexander Fish 1, Titia K Sixma 1,
PMCID: PMC8024992  PMID: 33619839

Abstract

During DNA replication, the deubiquitinating enzyme USP1 limits the recruitment of translesion polymerases by removing ubiquitin marks from PCNA to allow specific regulation of the translesion synthesis (TLS) pathway. USP1 activity depends on an allosteric activator, UAF1, and this is tightly controlled. In comparison to paralogs USP12 and USP46, USP1 contains three defined inserts and lacks the second WDR20‐mediated activation step. Here we show how inserts L1 and L3 together limit intrinsic USP1 activity and how this is relieved by UAF1. Intriguingly, insert L1 also conveys substrate‐dependent increase in USP1 activity through DNA and PCNA interactions, in a process that is independent of UAF1‐mediated activation. This study establishes insert L1 as an important regulatory hub within USP1 necessary for both substrate‐mediated activity enhancement and allosteric activation upon UAF1 binding.

Keywords: allostery, deubiquitinating enzyme, enzyme activity, quantitative kinetic modelling, translesion synthesis

Subject Categories: DNA Replication, Repair & Recombination; Post-translational Modifications, Proteolysis & Proteomics


Insert L1 of USP1 plays multiples roles in regulating USP1 activity. It contributes to inhibition that is relieved upon UAF1 binding and is important for interaction with DNA loaded PCNA.

graphic file with name EMBR-22-e51749-g010.jpg

Introduction

Dynamic regulation of ubiquitination on proteins involved in DNA repair pathways is essential for proper functioning of these pathways. (De)‐Ubiquitination enzymes that control these processes have gained a lot of attention, as these are attractive targets to attenuate DNA repair pathways. USP1 is a deubiquitinase (DUB) that acts on mono‐ubiquitinated PCNA and FANCD2, making it crucial for the regulation of translesion synthesis and the Fanconi anaemia pathway, respectively (Nijman et al, 2005; Huang et al, 2006). Recently, it was also shown that USP1 inhibition resulted in replication fork destabilization and decreased viability of BRCA1‐deficient cells indicating a synthetic lethal relationship (Lim et al, 2018). To target USP1 effectively, it would be important to know how its catalytic activity is regulated.

USP1 belongs to the ubiquitin‐specific protease (USP) family of DUBs, and it forms a small sub‐family with two other USPs, USP12 and USP46 (Mevissen & Komander, 2017). These USPs bind a common co‐factor called UAF1 (also known as WDR48), which leads to activation of these enzymes by an increase in the catalytic turnover (k cat) (Cohn et al, 2007, 2009). Relative to these paralogs, USP1 is much larger, primarily due to the presence of three inserts within its well‐conserved USP catalytic domain (Figs 1A and EV1A). It also lacks the binding site for another activator, WDR20, which binds USP12 and USP46, leading to further activation (Kee et al, 2010). In contrast, it was reported recently that USP1 activity is further enhanced upon binding DNA and this interaction is mediated by insert L1 of USP1 (Lim et al, 2018). Insert L1 was also shown to be the site of multiple phosphorylations (Villamil et al, 2012; Olazabal‐Herrero et al, 2015) and it has been reported to carry two nuclear localization signals that are important for its translocation to the nucleus (Garcia‐Santisteban et al, 2012).

Figure 1. UAF1 activates USP1 allosterically by relieving the insert 1 and insert 3 mediated auto‐inhibition of USP1 catalytic activity.

Figure 1

  1. Schematic diagram of the USP1 sub‐family and the USP1 deletion mutants tested in this study.
  2. Single point activity assays of USP1WT and deletion mutants on Ub‐Rho show significantly increased activity in mutants where inserts L1 and L3 are both deleted.
  3. Single point activity assays of USP1WT and deletion mutants (±UAF1) on Ub‐Rho show the loss in hyper‐activation of USP1ΔL1L3 upon addition of UAF1.
  4. Michaelis–Menten analysis of USP1 deletion mutants against ubiquitin‐rhodamine (Ub‐Rho) shows that USP1ΔL1L3 has significantly higher activity compared to WT and other mutants (n = 2, biological replicates).
  5. Michaelis–Menten analysis of USP1 deletion mutants (+UAF1) against Ub‐Rho shows that all deletions mutants have similar catalytic activity (n = 2, biological replicates).
  6. Comparing activity of USP1WT and USP1ΔL1L3 on a peptide substrate, i.e. LRGG‐AMC (100 µM). USP1ΔL1L3 cleaves the peptide substrate more efficiently compared to USP1WT (n = 2, technical replicates).
  7. Comparing activity of USP1WT and USP1ΔL1L3 (+UAF1) on a peptide substrate, i.e. LRGG‐AMC (100 µM). Addition of UAF1 allows cleavage of LRGG‐AMC by both USP1WT and USP1ΔL1L3 (n = 2, technical replicates).

Figure EV1. Structural and sequence alignment of USP1 relative to its paralogs highlights the 3 inserts of USP1.

Figure EV1

  1. Structure‐based sequence alignment of USP1, USP12 and USP46 shows the relative positioning of inserts within USP1 which are highlighted as following, insert 1 (red), insert 2 (green) and insert 3 (violet).
  2. Homology model of USP1 (dark blue) based on the structure of USP12 (light blue) bound to UAF1 and WDR20 (green) highlights the positioning of USP1 inserts relative to its catalytic domain.

So far there is no structural information available for USP1 alone or the USP1‐UAF1 complex, but crystal structures of the paralogs with and without the activators have been solved (Yin et al, 2015; Li et al, 2016; Dharadhar et al, 2016). Based on these USP12 and USP46 structures, it is clear that UAF1 binds USP1 on the “finger” sub‐domain of the catalytic domain (Yin et al, 2015). It has also been shown that UAF1 activation of USP12 is mainly caused by a series of subtle structural rearrangements in various parts of the enzyme. One such region is the proximal knuckle (PK) helix and its preceding loop called the PK loop which also form a part of the WDR20 interface (Li et al, 2016). Interestingly, USP1 has a small insertion of 20 amino acids in the PK loop and this insert is located in the WDR20 binding interface of USP12 and USP46 (Insert L3, Fig EV1B). Whether this small insert of USP1 plays any role in its activation by UAF1 and if there are other unique elements within USP1 which compensate for the lack of WDR20 activation are not known.

USP1 activity on FANCD2‐Ub is well studied and the N‐terminal extension of USP1 is important for activity on FANCD2 (Arkinson et al, 2018). DNA binding was shown to promote USP1‐UAF1 activity on FANCD2‐Ub, but in this case, activation is dependent on a DNA‐binding role of UAF1 (Liang et al, 2019). Additionally, the C‐terminal SUMO‐like domains (SLD) of UAF1 also play a role in the recruitment of USP1 to ubiquitinated substrates (Lee et al, 2010; Yang et al, 2011). In contrast, how USP1 acts on PCNA is not clear. Moreover, whether its activity is affected by DNA loading of PCNA‐Ub has not been studied. This may be important for USP1 activity as it is thought to travel along the replicating fork where it carries out its deubiquitinating activity in crucial DNA repair pathways (Dungrawala et al, 2015).

In this study, we demonstrate the molecular details of USP1 allosteric regulation by UAF1 and its natural substrate, i.e. DNA‐loaded PCNA‐Ub. We study the role of USP1 inserts on enzymatic activity towards substrates of increasing complexity. This reveals that the combined action of inserts L1 and L3 inhibits USP1 catalytic activity and that this auto‐inhibition is relieved by UAF1‐dependent activation on a minimal substrate (Ub‐Rho). On PCNA‐Ub, we find that a PIP motif in insert L1 is crucial for activity. Finally, we developed a protocol to load PCNA‐Ub on DNA. On this substrate, we identify a secondary enhancement in USP1 activity, that is only triggered upon interaction with DNA‐loaded PCNA‐Ub. Furthermore, we demonstrate that both DNA and PCNA interaction with USP1 are important for this substrate‐mediated increase in activity.

Results and Discussion

USP1 catalytic activity is inhibited by its inserts

To address the role of the inserts in USP1 catalytic activity, we made deletion mutants of USP1 that either lack each insert individually or in combinations (Fig 1A). These deletion mutants were successfully purified and their catalytic activities were tested against the minimal substrate ubiquitin‐rhodamine (Ub‐Rho). None of the variants lacking a single insert (USP1ΔL1, USP1ΔL2, USP1ΔL3) showed any change in activity compared to wild‐type USP1 (USP1WT), but when both inserts L1 and L3 were removed (USP1ΔL1L3), a significant hyper‐activation was observed (Fig 1B).

This hyper‐activation was unique to this combination, as deletion of inserts L1 and L2 (USP1ΔL1L2) or insert L2 and L3 (USP1ΔL2L3) did not affect USP1 catalytic activity (Fig 1B). The insert L3 in USP1 is located in the PK loop. In USP12, this loop is important for activation, as mutation of a stretch of glycine residues within the loop leads to loss in activation of USP12 by either UAF1 or WDR20. In USP1, deletion of insert L3 alone does not affect USP1 activity but the deletion of both insert L3 and insert L1 leads to an increased activity of USP1.

We tested whether phosphorylation of serine 313 in insert L1 had a direct effect on USP1 catalytic activity, since Ser313 phosphorylation was previously reported as necessary for UAF1 binding and its ability to activate (Villamil et al, 2012; Olazabal‐Herrero et al, 2015). We tested both the phospho‐dead (Ser to Ala) and phospho‐mimic (Ser to Asp) mutations, but neither showed an effect on activity of USP1 alone or upon binding with UAF1, relative to USP1WT (Fig EV2A).

Figure EV2. Activity assays of USP1 insert L1 mutants and a comparison of USP1 activity on PCNA‐Ub and PCNA‐UbTAMRA .

Figure EV2

  1. Single point activity assays of USP1WT, USP1S313A and USP1S313D (+UAF1) show no effect of these mutations on USP1 activity against the minimal substrate (Ub‐Rho).
  2. KinTek analysis of USP1ΔL1L3 and USP1WT activity on Ub‐rhodamine reveals that activation of USP1ΔL1L3 is due to an increase in k cat.
  3. Comparing activity of USP12‐UAF1 (±WDR20) on LRGG‐AMC (100 µM).
  4. Comparison of USP1‐UAF1 activity on PCNA‐Ub and PCNA‐UbTAMRA shows that the TAMRA label does not affect the rate of ubiquitin cleavage (n = 2, technical replicates).
  5. Single point activity assays of USP1WT, USP1ΔL1 and USP1PIP mutants (+UAF1) on Ub‐Rho show similar activity of all mutants compared to USP1WT.

We performed Michaelis–Menten kinetic analysis under increasing concentrations of Ub‐Rho substrate (Fig 1D, Table 1) and fitted USP1WT and all the deletion mutants. As the reaction velocity curves for USP1ΔL1L3 did not reach saturation, the estimation of Vmax and subsequently KM was not reliable. To validate our findings, we fitted USP1WT and USP1∆L1L3 activity data using KinTek Explorer (Johnson et al, 2009a) simultaneously, using all the data rather than initial rates only. Similar to our standard Michaelis–Menten analysis, this improved analysis again showed that the activation in USP1ΔL1L3 was mostly due to an increase in k cat (Fig EV2B). We conclude that inserts L1 and L3 together inhibit the intrinsic catalytic activity of USP1.

Table 1.

Kinetic analysis of USP1WT and deletion mutants using the Michaelis–Menten equation.

(−UAF1) (+UAF1)
k cat (s−1) KM (µM) k cat/KM (s−1 µM−1) k cat (s−1) KM (µM) k cat/KM (s−1 µM−1)
USP1WT 0.014 (±0.001) 3.80 (±0.52) 0.0036 0.73 (±0.03) 2.68 (±0.25) 0.272
USP1ΔL1 0.018 (±0.0007) 4.50 (±0.33) 0.0039 0.71 (±0.03) 2.53 (±0.23) 0.283
USP1ΔL2 0.004 (±0.0001) 1.03 (±0.11) 0.0043 0.80 (±0.03) 2.63 (±0.22) 0.306
USP1ΔL3 0.007 (±0.0003) 1.8 (±0.19) 0.0040 0.82 (±0.01) 2.03 (±0.09) 0.406
USP1ΔL1L3 0.26 (±0.01) 13.7 (±0.79) 0.019 1.01 (±0.07) 2.37 (±0.37) 0.425

UAF1 binding relieves insert L1‐ and insert L3‐mediated auto‐inhibition of USP1 activity

UAF1‐mediated activation of USP1 is primarily due to an increase in kcat (Cohn et al, 2007) which is similar to what we observe in USP1ΔL1L3. To test whether insert L1‐ and insert L3‐mediated auto‐inhibition of USP1 can be relieved by UAF1, we performed kinetic analysis in the presence of UAF1 on Ub‐Rho (Fig 1E). We observed that the hyper‐activation of USP1 that deletion of inserts L1 and L3 had caused was lost in the presence of UAF1, as the catalytic activity of USP1ΔL1L3 no longer differed significantly from USP1WT, nor from any of the other deletion mutants (Fig 1C and E, Table 1). These experiments also show that the deletion of insert L1 and insert L3 is not sufficient to completely recapitulate UAF1‐mediated activation as UAF1 binding can still activate USP1ΔL1L3. However, our data suggest that one of the primary mechanisms by which USP1 is activated by UAF1 is through relieving the auto‐inhibition caused by the joint action of inserts L1 and L3.

Based on the published structures of USP12 + UAF1 and USP12 + UAF1 + WDR20 (Li et al, 2016; Dharadhar et al, 2016), we generated a homology model of USP1, that shows the location of the inserts of USP1 (Fig EV1B). Interestingly, insert L3 of USP1 overlaps with the binding site of WDR20 in USP12 suggesting that the effect of WDR20 could be mimicked by a joint mechanism which involves rearrangement of both inserts L1 and L3.

A defining feature of WDR20‐dependent activation is that it is necessary for the ability of USP12 to cleave a peptide substrate, Leu‐Arg‐Gly‐Gly (LRGG)‐AMC, since USP12‐UAF1 alone cannot cleave such a substrate (Li et al, 2016). Therefore, we analysed whether USP1 could process this substrate. First, we compared USP1WT in the presence and absence of UAF1. Like USP12, USP1 alone cannot cleave the peptide substrate. However, addition of UAF1 is sufficient to activate USP1WT such that it can now process this substrate (Fig 1F and G), whereas USP12 requires WDR20 to make this happen (Fig EV2C; Li et al, 2016). Unlike USP1WT, the USP1ΔL1L3 alone can cleave the peptide substrate which is in line with the idea that rearrangement of insert L1 brings about conformational changes in insert L3 which are necessary for activation of USP1 by bringing it to a WDR20‐like state.

These results show on one hand that removal of insert L1‐ and insert L3‐mediated auto‐inhibition of USP1 brings it to a WDR20‐bound‐like state, and on the other hand that for USP1, the activation by UAF1 already achieves a state that requires WDR20 in the USP12/46 paralogs. It seems likely that this activation is mediated by some form of UAF1‐induced conformational change in inserts L1 and L3. When UAF1 binds, at the tip of the finger sub‐domain, this induces a cascade of rearrangements, as it does in USP12. We speculate that this brings about changes in insert L3, located at the base of the fingers and results in the removal of auto‐inhibition by inserts L1 and L3 (Fig EV1B). To understand how L1 and L3 mediate their inhibition structural information will be important.

Insert L1 is necessary for USP1 activity on PCNA‐Ub

To test whether the inserts of USP1 play any role in the deubiquitination of its natural substrate, i.e. mono‐ubiquitinated PCNA (PCNA‐Ub), we carried out activity assays on reconstituted PCNA‐Ub (Hibbert & Sixma, 2012). In these assays, we used a TAMRA label at the N terminus of ubiquitin for ease of quantitation (Dharadhar et al, 2019), as this has no effect on the rates (Fig EV2D). Comparing WT and deletion mutants, we observed that loss of insert L1 in USP1 severely impairs its ability to deubiquitinate PCNA‐UbTAMRA (Fig 2A), whereas this deletion does not affect activity on a minimal substrate.

Figure 2. Insert L1 of USP1 contains a PIP motif which is essential for activity of USP1 on PCNA‐Ub.

Figure 2

  1. Quantification of gel‐based activity assays where the activity of USP1WT and deletion mutants (+UAF1) on PCNA‐UbTAMRA is compared. The USP1ΔL1 mutant has reduced activity on PCNA‐UbTAMRA compared to the other USP1 variants tested (n = 2, biological replicates).
  2. Multiple sequence alignment of USP1 insert L1 which highlights the conservation of the PIP and APIM motif in USP1 across species, the residues mutated in this region are indicated with an asterisk.
  3. Quantification of gel‐based activity assays where the activity of USP1 PIP mutants (+UAF1) on PCNA‐UbTAMRA is compared. Both the PIP mutants have reduced activity on PCNA‐Ub compared to USP1WT (n = 2, biological replicates).
  4. FP‐based binding assays of USP1 mutants (+UAF1) with PCNA‐UbTAMRA show reduced binding of USP1ΔL1 and USP1PIP1 compared to USP1WT (n = 2, technical replicates).
  5. Quantification of gel‐based activity assays where the activity of USP1WT + UAF1 on PCNA‐UbWT is compared with PCNA‐UbPIM1 shows that PCNA‐UbWT is cleaved much faster compared to PCNA‐UbPIM1 (n = 2, technical replicates (example shown here from 1 of 2 biological replicates)).
  6. Comparing activity of USP1WT and USP1PIP1 (+UAF1) on PCNA‐UbWT and PCNA‐UbPIM1 in gel‐based assays shows that the activity of USP1WT is severely reduced by the PIM1 mutation in PCNA, whereas USP1PIP1 activity is not further affected indicating that PIP1 and PIM mutation affect the same interaction (n = 2, technical replicates (example shown here from 1 of 2 biological replicates)).

We analysed the sequence of insert L1 in a multi‐sequence alignment with different species (Fig 2B). We identified a degenerate PCNA‐interacting‐peptide (PIP) box, which is highly conserved across vertebrates (Fig 2B). Compared to traditional PIP motifs, there is one phenylalanine missing in the final FF, replaced by KF. Additionally, there was a possible APIM‐like motif just upstream of the PIP site. We made two mutants, a triple mutant in the PIP (PIP1: I351A, L352A and F355A) and one with additional changes in the APIM (PIP2: I351A, L352A and F355A; W341A, L342A and K343A). These mutants were co‐purified with UAF1 and tested for activity on PCNA‐UbTAMRA. Both USP1PIP1 and USP1PIP2 had reduced activity on PCNA‐UbTAMRA compared to USP1WT but were not affected in their activity on a minimal substrate (Figs 2C and EV2E).

Importantly, we then analysed binding of USP1 to PCNA‐Ub in a fluorescence polarization (FP) assay. Here we found that deletion of insert L1 (USP1ΔL1) or mutation of the PIP motif (PIP1) leads to a 10‐ and fivefold reduction in binding to PCNA‐UbTAMRA, respectively (Fig 2D).

To validate the role of the PIP interaction between USP1 and PCNA, we made mutations in PCNA (PIM1: L126A and I128A; PIM2: D232A and P234A; PIM3: P253A and K254A), in the PIP interaction site (Eissenberg et al, 1997). USP1WT activity was substantially reduced on the PCNA‐Ub PIM1 and PIM2 mutant, while the activity on the PIM3 mutant was the same when compared to PCNA‐Ub (WT) (Fig EV3A). We then compared the activity of USP1WT and USP1PIP1 on both PCNA‐UbPIM1 and PCNA‐UbWT. The activity of USP1WT was reduced on PCNA‐UbPIM1 but activity of USP1PIP1 was not further depleted on PCNA‐UbPIM1 relative to PCNA‐UbWT, indicating that both mutations affect the same interaction (Fig 2E and F). These binding and mutant data together confirm that insert L1 of USP1 contains a well‐conserved PIP motif which is important for USP1 interaction and activity on PCNA‐Ub.

Figure EV3. Testing efficiency of RFC‐mediated PCNA‐Ub loading and comparing activity of USP1 on PCNA‐UbPIM mutants.

Figure EV3

  1. Comparison of USP1 + UAF1 activity on PCNA‐UbWT and PCNA‐UbPIM mutants shows lower USP1 activity on PIM1 and PIM2 mutants.
  2. SPR‐based binding experiments show that USP1ΔL1 has a reduced affinity for double‐stranded DNA (65 bp) compared to USP1WT.
  3. RFC‐mediated PCNA‐Ub loading on nicked circular DNA has the same efficiency as loading of PCNA. Left Panel: Schematic representation of the purification of DNA‐loaded PCNA‐Ub. Right panel: Coomassie‐stained gel of fractions corresponding to the first (green) and second (orange) peak from SEC of the PCNA and PCNA‐Ub loading reactions, respectively.

Purification of PCNA‐Ub loaded on circular DNA

USP1‐UAF1 is known to play a role in PCNA‐Ub‐mediated translesion synthesis (Huang et al, 2006). Moreover, it has been suggested that USP1‐UAF1 travels with elongating replication forks where it deubiquitinates its substrates. Removal of USP1 from this environment was shown to generate increased ubiquitination of proteins residing at the fork (Dungrawala et al, 2015). Other studies have shown that both USP1 and UAF1 have DNA‐binding properties (Liang et al, 2016; Lim et al, 2018). We could confirm that USP1 binds DNA, and the fact that this interaction is dependent on insert L1 (Fig EV3B). However, we did not observe the (very small) effect on catalytic activity against a minimal substrate, Ub‐rhodamine (Lim et al, 2018; Fig 3B). Nevertheless, we wondered if the observed interaction with DNA could affect the activity on a more natural substrate, PCNA‐Ub loaded on DNA.

Figure 3. USP1 (±UAF1) has higher catalytic activity on PCNA‐Ub when it is loaded on DNA.

Figure 3

  1. Schematic representation of loading and purification of PCNA‐Ub on nicked circular DNA. The DNA‐loaded PCNA‐Ub elutes in the void of the SEC column, and this sample is collected and used for studying activity of USP1 on DNA‐loaded PCNA‐Ub.
  2. Michaelis–Menten analysis of USP1 + UAF1 with and without DNA (65 bp dsDNA) shows that DNA binding alone has no effect on USP1 activity (n = 2, technical replicates (example shown here from 1 of 2 biological replicates)).
  3. Coomassie‐stained gel of in vitro activity assay showing increased activity of USP1‐UAF1 on DNA‐loaded PCNA‐Ub compared to PCNA‐Ub (−DNA) and PCNA‐Ub (+DNA, +RFC and not ATP).
  4. Quantification of gel‐based activity assays showing enhanced activity of USP1 + UAF1 on DNA‐loaded PCNA‐Ub compared to free PCNA‐Ub (n = 3, technical replicates (example shown here from 1 of 2 biological replicates)).
  5. Quantification of gel‐based activity assays showing enhanced activity of USP1 on DNA‐loaded PCNA‐Ub compared to free PCNA‐Ub (n = 3, technical replicates (example shown here from 1 of 2 biological replicates)).

To enable analysis of USP1 activity on DNA‐loaded substrate, we established efficient DNA loading procedures for human PCNA‐Ub on circular DNA using the RFC clamp loader complex from yeast (Yoder & Burgers, 1991). First, we successfully purified PCNA‐Ub where each monomer of the clamp was mono‐ubiquitinated using previously published protocols (Hibbert & Sixma, 2012) and then we performed in vitro loading assays on nicked circular DNA (Fig 3A). Our results show that PCNA and PCNA‐Ub are loaded with similar efficiency onto nicked circular DNA (Fig EV3C). We then used size exclusion chromatography to obtain large amounts of purified PCNA‐Ub loaded on nicked circular DNA (Fig 3A). Due to the presence of a TAMRA label on each ubiquitin molecule, we could measure the exact concentrations of DNA‐loaded PCNA‐Ub which allowed us to perform quantitative in vitro deubiquitination assays.

The loading and purification of DNA‐loaded PCNA‐Ub is technically complex since many factors are involved in this reaction. Moreover, the half‐life of PCNA on DNA is approximately 25 min which makes downstream experiments challenging due to the time constraints (Zhao et al, 2017). We circumvented this problem by carrying out the activity assays within 20 min after elution from a size exclusion column.

USP1 deubiquitinates PCNA‐Ub more efficiently when it is loaded on DNA

We compared the deubiquitination activity of USP1 (±UAF1) on DNA‐loaded PCNA‐Ub with free PCNA‐Ub in a gel‐based activity assay. This showed that USP1‐mediated ubiquitin hydrolysis is much faster when PCNA‐Ub is loaded on DNA (Fig 3C–E). In these experiments, a minor fraction of the RFC co‐eluted with DNA‐loaded PCNA‐Ub which allowed reloading of PCNA‐Ub. However, this is not critical for the enhanced activity that we observe, as our control experiments with RFC and DNA in the absence of ATP do not show similar activity of USP1 (Fig 3C).

To obtain a detailed mechanism of USP1 activity, we performed kinetic analysis and modelling using the KinTek explorer software (Johnson et al, 2009a). We quantified USP1 (±UAF1) activity data under either different enzyme concentrations or different substrate concentrations against three different substrates, Ub‐Rho, PCNA‐Ub and DNA‐loaded PCNA‐Ub. We used SDS–PAGE‐based setup for DNA‐loaded PCNA‐Ub and free PCNA‐Ub (Figs 4A and EV4A). For PCNA‐Ub, we additionally performed fluorescence polarization (FP)‐based activity assays. Additionally, activity data of USP1 (±UAF1) on increasing concentrations of Ub‐rhodamine were also included (Figs 4B and EV4B). The resulting data only fit in a model where the enhanced activity on DNA‐loaded PCNA‐Ub is mediated by an increase in affinity of USP1 (±UAF1) for the substrate with no change in catalytic activity (Figs 4C and EV4C). The KinTek analysis allowed us to quantify the magnitude of enhanced USP1 activity both in the presence and absence of UAF1. We observed that loading of PCNA increases USP1 activity ~2‐fold, but in the presence of UAF1 the increase is fivefold (Fig 4C). The extra increase in USP1 activity given by UAF1 was caused by an increase in affinity for DNA‐loaded PCNA‐Ub of USP1 + UAF1, as the change is limited to KM. This observation corresponds well with previously published data which show that UAF1 itself has DNA‐binding properties in the range of 400 nM (Liang et al, 2019). To validate our kinetic modelling, we performed EMSA‐based binding analysis for USP1 (±UAF1) on DNA which confirmed that USP1‐UAF1 has stronger binding compared to USP1 alone (Fig EV4D). Altogether, our quantitative kinetic analysis shows that USP1 alone has enhanced activity on the natural substrate which is further strengthened when in complex with UAF1.

Figure 4. Modelling the enhanced USP1 activity on DNA‐loaded PCNA‐Ub.

Figure 4

  1. Gel‐based quantification of USP1‐UAF1 activity on PCNA‐Ub (DNA‐loaded and free) for three different concentration of enzyme and substrate.
  2. FP‐based activity assays on free PCNA‐Ub (three concentrations of USP1 and PCNA‐Ub) and activity of USP1 on increasing concentrations of Ub‐Rho.
  3. Kinetic model of USP1‐UAF1 activity on PCNA‐Ub and DNA‐loaded PCNA‐Ub (Ub‐Rho not shown here, see Fig EV4C for full model), constants with the same colour were linked during the fitting and they share same values.

Source data are available online for this figure.

Figure EV4. USP1 activity data used for KinTek analysis of USP1 on Ub‐Rho, free PCNA‐Ub and DNA‐loaded PCNA‐Ub.

Figure EV4

  1. Gel‐based quantification of USP1 activity on PCNA‐Ub (DNA‐loaded and free) for three different concentrations of enzyme and substrate.
  2. FP‐based activity assays on free PCNA‐Ub (three concentrations of USP1 and PCNA‐Ub) and activity of USP1 on increasing concentrations of Ub‐Rho.
  3. Full kinetic model of USP1 activity on three different substrates, constants with the same colour were linked during the fitting and they share same values.
  4. EMSA‐based DNA‐binding experiment validates our KinTek modelling as it shows that USP1‐UAF1 has a higher DNA‐binding capacity compared to USP1 alone.

Source data are available online for this figure.

Insert L1 is critical for enhanced activity of USP1 on DNA‐loaded PCNA‐Ub

To dissect how USP1 has higher activity on DNA‐loaded PCNA‐Ub, we compared how insert deletions affected the activity on DNA‐loaded PCNA‐Ub relative to free (unloaded) PCNA‐Ub. The USP1ΔL2 and USP1ΔL3 showed similar activity to USP1WT in cleaving PCNA‐Ub by loading on DNA, but the USP1ΔL1 mutant showed no increase in activity on the loaded substrate (Fig 5A). The activity of USP1ΔL1 on PCNA‐Ub is weak, and upon DNA loading its activity is not enhanced, in fact the activity is slightly lowered. These experiments show that the inserts L2 and L3 within USP1 are not involved in enhancing USP1 activity, while insert L1 is solely responsible for achieving this substrate‐dependent increase in USP1 activity.

Figure 5. Insert L1‐mediated DNA and PCNA interactions are crucial for increase in USP1 activity on DNA‐loaded PCNA‐Ub.

Figure 5

  1. Comparison of USP1WT and deletion mutants (+UAF1) for activity on DNA‐loaded PCNA‐Ub (solid lines) and free PCNA‐Ub (dashed lines) shows no increase in USP1ΔL1 activity on the loaded substrate. Left panel: Quantification of gel‐based activity assays showing percentage of cleaved PCNA‐Ub at the mentioned time points (n = 2, biological replicates). Right panel: Quantification of the activation fold observed in USP1WT and mutants on DNA‐loaded PCNA‐Ub vs. free PCNA‐Ub (n = 2, biological replicates).
  2. Multiple sequence alignment of USP1 insert L1 which highlights the DNA‐binding region and the conservation of the positively charged residues across species. Three groups of positively charged residues (***) are mutated separately and tested for binding to double‐stranded DNA (65 bp) using SPR which shows the importance of this region for DNA binding of USP1.
  3. Comparison of USP1DM1, USP1PIP1 and USP1PIP1+DM1 (+UAF1) activity on DNA‐loaded PCNA‐Ub (solid lines) and free PCNA‐Ub (dashed lines) shows reduced increase in activity of these mutants compared to USP1WT. Left panel: Quantification of gel‐based activity assays showing percentage of cleaved PCNA‐Ub at the mentioned time points (n = 2, technical replicates). Right panel: Quantification of the activation fold observed in USP1WT, USP1PIP1, USP1DM1 and USP1PIP1+DM1 on DNA‐loaded PCNA‐Ub vs. free PCNA‐Ub (n = 2, technical replicates).
  4. EMSA‐based DNA‐binding experiment shows that USP1PIP1 and USP1WT have similar DNA‐binding capability, while USP1DM1 has lost its ability to bind DNA.
  5. Schematic model for the role of insert L1 in USP1 activity regulation by UAF1 and DNA‐loaded PCNA‐Ub.

Since insert L1 has been previously shown to possess both PCNA‐ and DNA‐binding properties, we tested if both these functions could be responsible for increased USP1 activity on DNA‐loaded PCNA‐Ub, relative to PCNA‐Ub alone. To test how DNA binding could alter USP1 activity, we had to first identify residues involved in DNA binding so that we could separate the DNA‐ and PCNA‐binding roles of insert L1. We analysed the insert L1 sequence using multiple sequence alignment and identified a region within insert L1 with several positively charged residues, which are well conserved across vertebrates (Fig 5B). Insert L1 WT and three sets of triple mutants containing charge swaps were cloned and then purified for DNA‐binding studies using SPR. Our binding experiments showed that insert L1 can bind DNA, whereas all the triple mutants almost completely lost DNA binding (Fig 5B), thereby highlighting the role of electrostatic interaction in USP1 binding to DNA.

Insert L1‐mediated DNA and PCNA interactions are crucial for increasing USP1 activity on DNA‐loaded PCNA‐Ub

Insert L1 of USP1 is a large insert of 200 amino acids with two distinct well‐conserved regions for which we show interaction with DNA and PCNA, respectively. To gain further mechanistic insight into the insert L1‐mediated increase of USP1 activity, we compared the activity of a USP1 DNA‐binding mutant (USP1DM1; KKK281EEE) and a USP1 PCNA interaction mutant (USP1PIP1) on DNA‐loaded PCNA‐Ub with free PCNA‐Ub. In both mutants, the increase in activity on the DNA‐loaded substrate was substantially reduced relative to USP1WT (Fig 5C).

The USP1DM1 mutant also has reduced activity on free PCNA‐Ub compared to USP1WT. This means that we cannot fully confirm whether its loss in activity on the DNA‐loaded substrate is due to loss of DNA interaction. To delineate this further, we made a milder version (USP1DM2, KKK281AEA) of the original DNA‐binding mutant (USP1DM1). The USP1DM2 has similar activity on free PCNA‐Ub as USP1WT but still lost DNA‐binding ability when compared with USP1WT (Fig EV5A and B). When USP1DM2 was tested on DNA‐loaded, PCNA we found that it was poorly able to activate on this substrate, similar to USP1DM1 (Fig EV5C). Taken together, these mutants confirm that DNA interaction through insert 1 is important for enhanced USP1 activity on DNA‐loaded PCNA‐Ub.

Figure EV5. Studying the role of USP1DM mutants on DNA binding and activity on PCNA‐Ub.

Figure EV5

  1. Comparing activity of USP1 mutants on free PCNA‐Ub substrate (n = 2, technical replicates).
  2. EMSA‐based DNA‐binding experiment shows that USP1DM2 (AEA) has reduced binding compared to USP1WT.
  3. Comparing USP1 activity of DNA‐binding mutants and USP1WT on DNA‐loaded PCNA‐Ub (solid lines) and free PCNA‐Ub (dashed lines) shows reduced activation of the DNA‐binding mutants compared to USP1WT. Left panel: Quantification of gel‐based activity assays showing percentage of cleaved PCNA‐Ub at the mentioned time points (n = 2, technical replicates). Right panel: Quantification of the activation fold observed in USP1WT, USP1DM1 and USP1DM2 on DNA‐loaded PCNA‐Ub vs. free PCNA‐Ub (n = 2, technical replicates).

In contrast, the PCNA interaction mutant USP1PIP1 had retained the ability to bind DNA, in an electrophoretic mobility shift assay (EMSA) on a 65 bp dsDNA (Fig 5D). This indicates that USP1PIP1 is only affected in PCNA interaction and the loss of activity on DNA‐loaded PCNA‐Ub in this mutant is due to the defect in PCNA interaction.

Both the USP1DM1 and USP1PIP1 mutant still show considerable increase in activity on DNA‐loaded PCNA‐Ub, although to a lesser degree than USP1WT. Therefore, we generated a USP1 double mutant lacking both DNA and PCNA interactions (USP1PIP1+DM1) and compared its activity on DNA‐loaded PCNA‐Ub and free PCNA‐Ub. This double mutant has a very slightly enhanced activity on both substrates, but no significant difference between the two, indicating that it has completely lost the ability to enhance USP1 activity on DNA‐loaded PCNA‐Ub (Fig 5C). The complete loss of substrate‐mediated activity increase in this USP1 mutant shows that PCNA interaction and DNA interaction together are necessary and sufficient for the increase in USP1 activity.

Altogether, these experiments establish insert L1 as a central regulatory hub for USP1 activity and highlight the role of various elements which play a role in allosteric regulation of USP1 activity. These mutations could be used for validation in vivo, but unfortunately the DNA‐binding site overlaps with the previously assigned NLS, suggesting some difficulties in separating these functions out, Nevertheless, these newly identified USP1 hotspots are important as they may serve as novel starting points for development of specific allosteric modulators of USP1 function.

USP1 is activated by two distinct mechanisms involving UAF1 and DNA‐loaded PCNA‐Ub

The activation of USP1 by UAF1 takes place through an allosteric mechanism where the catalytic turnover (kcat) of the enzyme is increased several fold (Cohn et al, 2007). We have shown here that this activation requires the rearrangement of inserts L1 and L3 which auto‐inhibit USP1 in the absence of UAF1 (Fig 1D and E; Table 1). In this study, we also uncover a secondary step that enhances USP1 activity which is caused upon interaction with DNA‐loaded PCNA‐Ub.

Based on our preliminary biochemical analysis, we assumed that the increase in USP1 activity on DNA‐loaded PCNA‐Ub takes place solely through a change in the affinity of the enzyme for the loaded substrate vs. the unloaded substrate, as cleavage rate values remained similar in individual runs. Therefore, they were linked in the final analysis accordingly (Fig EV4, Table 2).

Table 2.

KinTek modelling of USP1 (±UAF1) activity on three substrates, i.e. Ub‐Rho, PCNA‐Ub and DNA‐loaded PCNA‐Ub.

Units −UAF1 +UAF1
Ub‐Rho PCNA‐Ub DNA‐PCNA‐Ub Ub‐Rho PCNA‐Ub DNA‐PCNA‐Ub
k on a µM−1 s−1 100α 100α 100α 100α 100α 100α
k off a s−1 594 ± 24β 930 ± 31γ 433 ± 8 594 ± 24β 930 ± 31γ 183 ± 10
k cat (k cut) a , b s−1 0.021 ± 0.001δ 0.021 ± 0.001δ 0.021 ± 0.001δ 1.66 ± 0.05ε 1.66 ± 0.05ε 1.66 ± 0.05ε
KM µM 5.94 ± 0.24 9.3 ± 0.31 4.33 ± 0.08 5.94 ± 0.24 9.3 ± 0.31 1.83 ± 0.01
k cat/KM µM−1 s−1 0.0035 ± 0.0002 0.0023 ± 0.0001 0.0048 ± 0.0002 0.279 ± 0.014 0.178 ± 0.008 0.907 ± 0.027
a

Constants with the same symbol (α, β, γ, δ) were linked during the fitting, and they share same values.

b

Although k cut mathematically is not equivalent to Michaelis–Menten catalytic rate constant k cat, the difference in the values between them in this model is neglectable in comparison to measurement and fitting errors.

Interestingly, we note that not only USP1‐UAF1 is activated by DNA loading of PCNA, but also USP1 alone, which shows an increase in catalytic efficiency of from 2.3 mM−1 s−1 to 4.8 mM−1 s−1. This confirms that also in the absence of UAF1, USP1 has higher activity on the DNA‐loaded substrate. The PCNA and DNA interaction regions of insert L1 are likely to play a key role in this since we have shown that mutating these two regions leads to no increase in activity.

Nevertheless, the increase in activity is larger in the presence of UAF1, increasing from 178 mM−1 s−1 on PCNA‐Ub to 907 mM−1 s−1 on DNA‐loaded PCNA‐Ub (Table 2, Fig 4C), primarily due to a difference in K off. In both USP1 and USP1‐UAF1, the enzyme is faster on DNA‐loaded PCNA‐Ub, but the increase in activity due to DNA loading is higher in the presence of UAF1: fivefold increase in USP1‐UAF1 and a twofold increase in USP1 alone (Table 2, Fig 4C).

Recently, it has been shown that USP1 activity on Ub‐FANCD2 is higher in the presence of DNA and this is dependent on UAF1 binding (Liang et al, 2019). This suggests that the DNA interaction of UAF1 may help to increase the affinity of USP1 for DNA‐loaded PCNA‐Ub (Figs 4 and EV4). Apparently, USP1 activity is regulated by two separate mechanisms, one which involves the change in catalytic turnover upon UAF1 binding, while the other involves a change in affinity towards its natural substrate, i.e. DNA‐loaded PCNA‐Ub (Fig 5E). Therefore, we propose that UAF1 activation and DNA‐loaded PCNA‐Ub‐mediated enhancement of USP1 activity are mechanistically independent of each other.

Materials and Methods

Plasmids and cloning

Human USP1 and UAF1 (WDR48) constructs were obtained from Martin Cohn (University of Oxford). Human WDR20 (isoform 5) was subcloned from the HAP1 cell line (Essletzbichler et al, 2014) into pGEXNKI‐GST3C‐LIC vector (Luna‐Vargas et al, 2011) for expression in Escherichia coli. Plasmid pBL481 for overexpression of the entire RFC complex was a gift from Peter Burgers (Washington University, St. Louis). A 1.7 Kb circular plasmid (RC1766) used for PCNA‐Ub loading was a gift from Rafael Fernández Leiro (CNIO, Madrid). The USP1 constructs were all cloned in the pFastbac‐HTb vector (N‐terminal His tag), with a G670A + G671A mutation to prevent autocleavage of the USP1 protein (Huang et al, 2006). The UAF1 construct was cloned into the pFastbac1 vector (N‐terminal Strep tag) for expression in Spodoptera frugiperda (sf9) cells. USP1 point mutants were generated using QuikChange site‐directed mutagenesis, and mutants were confirmed by sequencing. The AEA mutant of USP1 contains an additional M583I cloning mutation. USP1 insert 1 (230–420) was cloned into the pGEXNKI‐GST3C‐LIC vector, and the CysUbiquitin construct was cloned into the pETNKI‐His‐SUMO2‐kan vector for expression in E. coli (Luna‐Vargas et al, 2011). Plasmids used for PCNA, Uba1 (E1), UbCH5C (S22R), ubiquitin have been described previously (Hibbert & Sixma, 2012).

Protein expression and purification

Complexes of recombinant UAF1 with USP1 wild‐type and mutant proteins (USP1KKK281EEE, USP1PIP1,2, USP1 insert deletions) were co‐expressed and co‐purified from sf9 cells as described previously (Dharadhar et al, 2019). Complex of USP12‐UAF1 protein was co‐expressed and co‐purified from sf9 cells as described previously (Dharadhar et al, 2016). PCNA, UBA1, ubiquitin and UbCH5c (S22R) (UBE2D3) were expressed and purified from E. coli as described previously (Hibbert & Sixma, 2012).

Purification of USP1

In experiments where USP1 was used without UAF1, both USP1 wild‐type and deletion mutants were expressed by Baculovirus expression in sf9 cells for 72 h by infecting cells at a density of 1 × 106 cells ml−1. Cells were harvested in lysis buffer (50 mM Tris pH 8.0, 200 mM NaCl, 5 mM TCEP) with complete EDTA‐free protease inhibitor (Sigma) and lysed by sonication. The lysed cells were spun down (53,000 × g for 30 min) in a high‐speed centrifuge at 4°C, and the supernatant was loaded on a column of Ni2+‐Sepharose beads pre‐equilibrated in lysis buffer. Once the supernatant had passed through the column, it was washed with 30 column volumes (CV) of wash buffer (lysis buffer + 20 mM Imidazole pH 8.0) and then USP1 was eluted with 5CV of elution buffer (lysis buffer + 500 mM Imidazole pH 8.0). The elution fraction was diluted twofold with 50 mM Tris pH 8.0 and loaded on an anion exchange column (Resource Q, GE Healthcare) pre‐equilibrated with 50 mM Tris pH 8.0, 100 mM NaCl, 2 mM DTT (IEX buffer). The column was washed with 3CV of IEX buffer and elution was carried out by applying a salt gradient of 20CV from 100 mM to 1 M NaCl. Fractions containing USP1 were combined and concentrated at 4°C in an Amicon Ultra‐15 centrifugal filter unit (30 kDa cut‐off; Merck) and then loaded on a size exclusion column (Superdex 200 10/300; GE) equilibrated in 20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM DTT (SEC buffer). Pure USP1 fractions were concentrated at 4°C and stored at −80°C.

Purification of USP1 insert L1

Insert L1 wild‐type and mutant proteins were expressed in BL21 (E. coli) cells by inducing cells at an OD of 0.8 with 0.2 mM IPTG followed by overnight expression at 18°C. Cells were harvested in lysis buffer (50 mM Tris pH 8.0, 200 mM NaCl, 2 mM DTT) with complete EDTA‐free protease inhibitor (Sigma) and lysed by sonication. The lysed cells were spun down (53,000 × g for 30 min) in a high‐speed centrifuge at 4°C, and the lysate was loaded on a column of Glutathione Sepharose 4B beads (GE Healthcare) pre‐equilibrated in lysis buffer. Once the lysate had passed through the column, it was washed with 30CV of lysis buffer following which insert 1 was eluted with 5CV of elution buffer (lysis buffer + 50 mM reduced glutathione). GST‐tag was cleaved in 2 h with 3°C protease while dialysing against 20 mM Tris pH 8.0, 100 mM NaCl, 2 mM DTT (Heparin buffer). The sample was collected from the dialysis bag and loaded on a Heparin column (GE Healthcare) pre‐equilibrated in Heparin buffer. After sample application, the column was washed with 3CV of Heparin buffer and protein was eluted using a salt gradient of 20CV from 100 mM to 1 M NaCl. Fractions containing pure insert 1 were combined and concentrated at 4°C in an Amicon Ultra‐15 centrifugal filter unit (10 kDa cut‐off; Merck) and then loaded on a size exclusion column (Superdex 200 10/300; GE) equilibrated in SEC buffer. Pure insert 1 fractions were concentrated at 4°C and stored at −80°C.

Purification of GST‐WDR20

GST‐WDR20 was expressed in BL21 (E. coli) cells by inducing at an OD of 0.8 with 0.2 mM IPTG followed by overnight expression at 18°C. Cells were harvested in lysis buffer (50 mM Tris pH 7.5, 200 mM NaCl, 2 mM DTT) with complete EDTA‐free protease inhibitor (Sigma) and lysed by sonication. The lysed cells were spun down (53,000 × g for 30 min), and the clarified lysate was loaded on a column of Glutathione Sepharose 4B beads (GE Healthcare) pre‐equilibrated in lysis buffer. The beads were incubated with the lysate for 30 min at 4°C, and then, the lysate was allowed to pass through the column. The beads were washed with 30CV of lysis buffer, and GST‐WDR20 was eluted in 5CV of lysis buffer with 20 mM reduced glutathione. The eluted sample was then loaded on a cation exchange column (POROS S, GE Healthcare) pre‐equilibrated with 20 mM Tris pH 7.5, 200 mM NaCl, 2 mM DTT (IEX buffer). GST‐WDR20 eluted upon applying a salt gradient of 10CV from 200 to 1,000 mM NaCl. Fractions containing GST‐WDR20 were combined and concentrated at 4°C in an Amicon Ultra‐15 centrifugal filter unit (30 kDa cut‐off; Merck).

Purification of PCNA‐UbTAMRA

Ubiquitin with a cysteine residue introduced at the N terminus after the methionine at position 1 (CysUbiquitin) was labelled using maleimide linked TAMRA dye (Setareh Biotech). The purification of CysUbiquitin and its labelling with maleimide linked TAMRA has been described previously (Dharadhar et al, 2019).

The components required for the in vitro mono‐ubiquitination of PCNA are UbTAMRA, Uba1, PCNA and UbCH5c (S22R) (UBE2D3). Once all the components were purified, the reaction was setup as described previously to a final reaction volume of 20 ml (Hibbert & Sixma, 2012). Upon completion of the reaction, the PCNA‐UbTAMRA was purified from the rest of the components using anion exchange chromatography followed by size exclusion chromatography in GF buffer. The purified sample was concentrated at 4°C in an Amicon Ultra‐15 centrifugal filter unit (10 kDa cut‐off; Merck) and stored at −80°C.

Purification of RFC

The procedure for the purification of the RFC complex was adapted from a previously described protocol by the Burgers laboratory (Gomes et al, 2000). Protein was expressed in E. coli grown in Terrific broth (TB) medium. Cells were induced at an OD of 1.6 with 0.2 mM IPTG followed by overnight expression at 16°C. The cells were harvested in lysis buffer (30 mM HEPES 7.5, 200 mM NaCl, 1 mM DTT, 0.5 mM EDTA, 10% Glycerol, 0.5 mM PMSF, complete protease inhibitor) and lysed by sonication. The lysed cells were kept stirring on ice and 0.5% Polymin P was added followed by incubation for 5 min. The lysed cells were spun down at 53,000 × g for 40 min at 4°C, and the supernatant was collected. Ammonium sulphate (0.28 g ml−1) was added to the supernatant while stirring on ice for 30 min and then the precipitated proteins were collected by spinning at 12,000 × g for 60 min. The proteins were resuspended in 30 mM HEPES 7.5, 1 mM DTT, 0.5 mM EDTA, 10% Glycerol, 0.5 mM PMSF, complete protease inhibitor followed by dialysis for 2 h against 30 mM HEPES 7.5, 100 mM NaCl, 1 mM DTT, 0.5 mM EDTA, 10% Glycerol. The dialysed sample was loaded on a cation exchange column (POROS S 6 ml, GE Healthcare) pre‐equilibrated in 30 mM HEPES 7.5, 100 mM NaCl, 1 mM TCEP, 10% Glycerol (PorosS buffer). Subsequently, the column was washed with 5CV of PorosS buffer and the protein was eluted by applying a salt gradient from 100 mM to 1 M NaCl. The fractions containing all five subunits of RFC are collected and loaded on Ni2+‐Sepharose beads pre‐equilibrated in 20 mM HEPES 7.5, 200 mM NaCl, 10% Glycerol, 1 mM TCEP (His buffer). The column is then washed with 30CV of wash buffer (His buffer + 20 mM Imidazole pH 8.0), and the protein is eluted with 5CV of elution buffer (20 mM HEPES pH 7.5, 300 mM NaCl, 300 mM Imidazole pH 8.0, 10% Glycerol, 1 mM TCEP, 0.05% Ampholytes). Sample was concentrated at 4°C in an Amicon Ultra‐15 centrifugal filter unit (10 kDa cut‐off; Merck) and then loaded on a size exclusion column (Superdex 200 10/300; GE) equilibrated in 20 mM HEPES pH 7.5, 200 mM NaCl, 10% Glycerol, 1 mM DTT, 0.05% Ampholytes. Fractions containing the RFC complex were concentrated at 4°C and stored at −80°C.

Production of nicked circular DNA

The RC1766 plasmid was nicked using a nicking endonuclease, Nt.BbvCI. The nicked circular DNA was then loaded on a size exclusion column (Superose 6 10/300; GE) equilibrated in 20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM DTT. The fractions containing the nicked circular DNA were collected and concentrated in an Amicon Ultra‐15 centrifugal filter unit (10 kDa cut‐off; Merck) up to a final concentration of 1 µM.

Purification of DNA‐loaded PCNA‐Ub

To load PCNA‐Ub on DNA, we added 10 µM PCNA‐Ub, 0.2 µM nicked circular DNA and 1 µM RFC in 20 mM HEPES pH 7.5, 150 mM NaCl, 10 mM MgCl2, 2 mM ATP, 1 mM DTT at a final volume of 500 µl. The reaction was incubated at 4°C for 2 h and then it was injected on a size exclusion column (Superose 6 10/300; GE) pre‐equilibrated in 20 mM HEPES pH 7.5, 100 mM NaCl, 10 mM MgCl2, 0.5 mM ATP, 1 mM DTT. DNA‐loaded PCNA‐Ub elutes at the void volume of the column and is ready to be used for downstream applications.

Ub‐rhodamine activity assays

Enzymatic activity was followed as release of fluorescent rhodamine from the quenched Ub‐rhodamine substrate (UbiQ; The Netherlands), providing a direct readout for DUB activity. The fluorescence intensity at 590 nm was measured using the Pherastar plate reader (BMG LABTECH GmbH, Germany). The assays were carried out in 384‐well plates (Corning, flat bottom, low flange) at 25°C in a reaction buffer of 20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM DTT, 0.05% Tween‐20. Single point assays were carried out at 1 µM substrate concentration and different enzyme concentrations. The enzyme concentrations used are indicated in the figure. For the Michaelis–Menten analysis, 100 nM of USP1 and 10 nM of USP1‐UAF1 were used against different substrate concentration starting from 5 to 0.1 µM. The initial velocity rates were obtained from the slopes of the linear phase of the curve. These rates were plotted against substrate concentration and fitted with a Michaelis–Menten model using non‐linear regression in GraphPad Prism 7 software (GraphPad Software Inc., USA). Since the reaction velocity of USP1L1L3 has not reached saturation, the KM values obtained by this approach are unreliable. Therefore, the USP1ΔL1L3 activity curves were fitted in addition using Kintek Explorer version 8.0 (Kintek Corporation (Johnson et al, 2009a)) alongside USP1WT to establish if there is indeed a real change in the KM values between the two enzymes.

Peptide substrate LRGG‐AMC activity studies

Enzymatic activity was followed as a release of fluorescent AMC from the quenched LRGG‐AMC substrate (Boston Biochem), providing a direct readout for DUB activity on a minimal peptide. The fluorescence intensity at 440 nm was measured using the Pherastar plate reader (BMG LABTECH GmbH, Germany). The assays were carried out in 384‐well plates (Corning, flat bottom, low flange) at 25°C in a reaction buffer of 20 mM HEPES pH 7.5, 150 mM NaCl, 5 mM DTT, 0.05% Tween‐20. USP1 WT and mutants were tested at different concentrations against 100 µM of LRGG‐AMC, and enzyme concentrations used are indicated in the figures.

Fluorescence polarization‐based binding assay

The FP assays were carried out in 384‐well plates at 25°C in a reaction buffer of 20 mM HEPES pH 7.5, 100 mM NaCl, 2 mM DTT, 0.05% Tween‐20. All USP1‐UAF1 mutants tested also had their active site cysteine mutated to alanine which resulted in catalytically dead USP1‐UAF1. These mutants were tested for binding to PCNA‐UbTAMRA by measuring FP at varying concentrations of USP1‐UAF1 (5 µM–80 nM) while keeping the PCNA‐UbTAMRA at a constant concentration of 25 nM. The FP measurements were taken in the Pherastar plate reader (BMG LABTECH GmbH, Germany), using excitation wavelength of 540 nm (±20), and the polarization was detected at 590 nm (±20). The initial polarization of PCNA‐UbTAMRA was set at 30 mp, and any increase in polarization upon binding of USP1‐UAF1 was plotted using GraphPad Prism 7 (GraphPad software Inc., USA).

SPR‐based binding assay

SPR binding experiments were carried out in the Biacore T200 system (GE, USA) to test the binding of USP1 WT and mutants with double‐stranded DNA. The running buffer used for the SPR experiment was 20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM DTT, 0.05% Tween‐20, 1 mg ml−1 BSA and the DNA was immobilized on a Streptavidin chip (Sensor chip SA, GE) using the biotin present on the 5′ end of the DNA. The binding experiments were carried out in the single cycle kinetics mode with 10 sequential injections of USP1 and USP1ΔL1 from 25 to 0.05 µM, while the insert 1 and mutants were injected from 100 to 0.2 µM. Data from a reference flow cell (−DNA) which was run in parallel to the experiment were subtracted from the signal using the Biacore T200 evaluation software. The final analysis and figures were done in GraphPad Prism 7 software (GraphPad Software Inc, USA).

Electrophoretic mobility shift assays

USP1 binding to DNA was also tested by performing EMSAs with native 4–12% pre‐cast Tris‐Glycine gels at 4°C (Life Technologies). The gels were equilibrated by running them in Tris‐Glycine buffer at 125 V for 90 min at 4°C prior to the start of the actual experiment. USP1 and mutants were serially diluted to make a twofold dilution series from 2.5 to 0.3 µM, and the DNA was added to a final concentration of 0.2 µM. The USP1‐DNA samples were incubated at 4°C for 15 min prior to loading in the pre‐equilibrated gel which was then run at 125 V for 90 min at 4°C. DNA bands were visualized by GelRed staining followed by imaging in a ChemiDoc XRS instrument (Bio‐Rad).

Gel‐based activity assays

PCNA‐UbTAMRA cleavage assays were performed in a reaction buffer composed of 20 mM HEPES pH 7.5, 100 mM NaCl, 5 mM MgCl2, 0.25 mM ATP, 2 mM DTT. The cleavage reaction was started by addition of USP1 (±UAF1) followed by incubation at room temperature for the specified time course. The concentration of DUB used for the kinetic modelling experiments was 1, 0.5, 0.25 µM for USP1 and 20, 10, 5 nM for USP1‐UAF1. All the mutants tested for activity on PCNA‐UbTAMRA were in complex with UAF1, and they were run in parallel with wild‐type USP1 at a concentration of 25 nM. Samples were collected at the indicated time points, and the reaction was stopped by adding SDS loading buffer. Samples were loaded on NuPAGE 4–12% Bis‐Tris SDS gel (Invitrogen) and separated by running them at 180 V for 30 min. The TAMRA fluorescence signal was visualized using a Typhoon FLA‐9500 gel scanner (GE Healthcare), and the concentration of PCNA‐UbTAMRA and ubiquitin was quantified by comparing the TAMRA fluorescence of the individual bands with a calibration curve of TAMRA fluorescence in the same experimental setting.

Kinetic modelling of USP1 activity on DNA‐loaded and free PCNA‐Ub

Kintek Explorer version 8.0 (Kintek Corporation (Johnson et al, 2009a)) was used to fit the reaction mechanism. Cleavage data from three different substrates, i.e. Ub‐rhodamine, PCNA‐Ub and DNA‐loaded PCNA (Figs 4 and EV4), were used for the fitting simultaneously. The fitting presented here is based on all the data, but the model was built in stages. At first step, enzymatic activity assay data of USP1 and USP1‐UAF1 on minimal substrate Ub‐rhodamine were fitted to a product inhibition model, which includes three steps: substrate binding, substrate cleavage and product release. The association rate constants of substrate and product binding (k on) were set to diffusion limit approximation (100 µM−1 s−1), and dissociation rate constants substrate and product (k off) share the same value in both reactions. The results of the fitting (k cat, K M and k cat/K M) were compared with the results of Michaelis–Menten calculations (Table 1).

kcat=kcutkoffkcut+koff
KM=koffkon
kcat/KM=kcutkonkcut+koff

k cut—cleavage rate constant;

k on—substrate and product binding rate constant;

k off—substrate and product dissociation rate constant

Next, the enzymatic activity FP assay data on PCNA‐UbTAMRA substrate were added to the analysis. Same model was used and in addition to previous constrains cleavage rate constant (k cut) was shared same value for each enzyme, and k off shared same value in the reactions with same substrate. In addition, concentrations of enzymes and substrates were allowed to vary up to 5% from the theoretical value in order to compensate for experimental pipetting error. At the last step of model building, the data from gel‐based enzymatic activity assays on PCNA‐UbTAMRA and DNA‐loaded PCNA‐UbTAMRA substrates were added to the analysis. Same model and rate constraints were used for the fitting. However, it was not possible to achieve good global fit of the date unless the value of k off for USP1 in reaction with DNA‐loaded PCNA‐UbTAMRA was different from the value of k off for USP1‐UAF1 in reaction with DNA‐loaded PCNA‐UbTAMRA. Solution landscape analysis of the fitted parameters was done using FitSpace Editor (Johnson et al, 2009b). It showed correlation between values of k off and k cut. Thus, only their ratios and magnitude are directly defined within the model, meaning that the values of kinetic efficiency (k cat/KM) are giving the best representation of the modelling results.

Author contributions

SD designed, performed and analysed biochemical experiments with assistance from TKS and AF. SD and SS performed mutant design and cloning. SD, SS and WJvD performed protein purification. Kinetic modelling using the KinTek software was done by AF. SPR experiments were done by SD and AF. TKS conceived and coordinated the study, and SD wrote the paper with assistance from TKS. All authors reviewed the results and approved the final version of the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Supporting information

Expanded View Figures PDF

Source Data for Expanded View

Review Process File

Source Data for Figure 4

Acknowledgements

We thank Niels Keizer and Andrea Murachelli for critical reading of the manuscript and other group members for their helpful suggestions. We thank Peter Burgers for the RFC construct and Martin Cohn for USP1 and UAF1 constructs. We thank Athanassios Adamopoulos for help with mutant cloning. We thank Farid El Oualid for providing us with Ub‐rhodamine. The authors acknowledge funding from the Dutch Cancer Society (KWF 2014‐6858) and Oncode Institute.

EMBO Reports (2021) 22: e51749.

Data availability

This study includes no data deposited in external repositories.

References

  1. Arkinson C, Chaugule VK, Toth R, Walden H (2018) Specificity for deubiquitination of monoubiquitinated FANCD2 is driven by the N‐terminus of USP1. Life Sci Alliance 1: 1–15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cohn MA, Kowal P, Yang K, Haas W, Huang TT, Gygi SP, D’Andrea AD (2007) A UAF1‐containing multisubunit protein complex regulates the fanconi anemia pathway. Mol Cell 28: 786–797 [DOI] [PubMed] [Google Scholar]
  3. Cohn MA, Kee Y, Haas W, Gygi SP, D’Andrea AD (2009) UAF1 is a subunit of multiple deubiquitinating enzyme complexes. J Biol Chem 284: 5343–5351 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dharadhar S, Clerici M, Van DWJ, Fish A, Sixma TK (2016) A conserved two‐step binding for the UAF1 regulator to the USP12 deubiquitinating enzyme. J Struct Biol 196: 437–447 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dharadhar S, Kim RQ, Uckelmann M, Sixma TK (2019) Quantitative analysis of USP activity in vitro, 1st edn, Amsterdam: Elsevier Inc. [DOI] [PubMed] [Google Scholar]
  6. Dungrawala H, Rose KL, Bhat KP, Mohni KN, Glick GG, Couch FB, Cortez D (2015) The replication checkpoint prevents two types of fork collapse without regulating replisome stability. Mol Cell 59: 998–1010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eissenberg JC, Ayyagari R, Gomes XV, Burgers PM (1997) Mutations in yeast proliferating cell nuclear antigen define distinct sites for interaction with DNA polymerase delta and DNA polymerase epsilon. Mol Cell Biol 17: 6367–6378 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Essletzbichler P, Konopka T, Santoro F, Chen D, Gapp BV, Kralovics R, Brummelkamp TR, Nijman SMB, Bürckstümmer T (2014) Megabase‐scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line. Genome Res 24: 2059–2065 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Garcia‐Santisteban I, Zorroza K, Rodriguez JA (2012) Two nuclear localization signals in USP1 mediate nuclear import of the USP1/UAF1 complex. PLoS One 7: e38570 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gomes XV, Gary SL, Burgers PMJ (2000) Overproduction in Escherichia coli and characterization of yeast replication factor C lacking the ligase homology domain. J Biol Chem 275: 14541–14549 [DOI] [PubMed] [Google Scholar]
  11. Hibbert RG, Sixma TK (2012) Intrinsic flexibility of ubiquitin on proliferating cell nuclear antigen (PCNA) in translesion synthesis. J Biol Chem 287: 39216–39223 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Huang TT, Nijman SMB, Mirchandani KD, Galardy PJ, Cohn MA, Haas W, Gygi SP, Ploegh HL, Bernards R, D’Andrea AD (2006) Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol 8: 339–347 [DOI] [PubMed] [Google Scholar]
  13. Johnson KA, Simpson ZB, Blom T (2009a) Global Kinetic Explorer: a new computer program for dynamic simulation and fitting of kinetic data. Anal Biochem 387: 20–29 [DOI] [PubMed] [Google Scholar]
  14. Johnson KA, Simpson ZB, Blom T (2009b) FitSpace Explorer: an algorithm to evaluate multidimensional parameter space in fitting kinetic data. Anal Biochem 387: 30–41 [DOI] [PubMed] [Google Scholar]
  15. Kee Y, Yang K, Cohn MA, Haas W, Gygi SP, D’Andrea AD (2010) WDR20 regulates activity of the USP12.UAF1 deubiquitinating enzyme complex. J Biol Chem 285: 11252–11257 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lee KY, Yang K, Cohn MA, Sikdar N, D’Andrea AD, Myung K (2010) Human ELG1 regulates the level of ubiquitinated proliferating cell nuclear antigen (PCNA) through its interactions with PCNA and USP1. J Biol Chem 285: 10362–10369 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Li H, Lim KS, Kim H, Hinds TR, Jo U, Mao H, Weller CE, Sun J, Chatterjee C, D’Andrea AD et al (2016) Allosteric activation of ubiquitin‐specific proteases by β‐propeller proteins UAF1 and WDR20. Mol Cell 63: 249–260 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Liang F, Longerich S, Miller AS, Tang C, Buzovetsky O, Xiong Y, Maranon DG, Wiese C, Kupfer GM, Sung P (2016) Promotion of RAD51‐mediated homologous DNA pairing by the RAD51AP1‐UAF1 complex. Cell Rep 15: 2118–2126 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Liang F, Miller AS, Longerich S, Tang C, Maranon D, Williamson EA, Hromas R, Wiese C, Kupfer GM, Sung P (2019) DNA requirement in FANCD2 deubiquitination by USP1‐UAF1‐RAD51AP1 in the Fanconi anemia DNA damage response. Nat Commun 10: 1–8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lim KS, Li H, Roberts EA, Gaudiano EF, Clairmont C, Sambel LA, Ponnienselvan K, Liu JC, Yang C, Kozono D et al (2018) USP1 Is required for replication fork protection in BRCA1‐deficient tumors. Mol Cell 72: 925–941.e4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Luna‐Vargas MPA, Christodoulou E, Alfieri A, van Dijk WJ, Stadnik M, Hibbert RG, Sahtoe DD, Clerici M, De MV, Littler D et al (2011) Enabling high‐throughput ligation‐independent cloning and protein expression for the family of ubiquitin specific proteases. J Struct Biol 175: 113–119 [DOI] [PubMed] [Google Scholar]
  22. Mevissen TET, Komander D (2017) Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem 86: 159–192 [DOI] [PubMed] [Google Scholar]
  23. Nijman SMB, Huang TT, Dirac AMG, Brummelkamp TR, Kerkhoven RM, D’Andrea AD, Bernards R (2005) The deubiquitinating enzyme USP1 regulates the fanconi anemia pathway. Mol Cell 17: 331–339 [DOI] [PubMed] [Google Scholar]
  24. Olazabal‐Herrero A, García‐Santisteban I, Rodríguez JA (2015) Structure‐function analysis of USP1: insights into the role of Ser313 phosphorylation site and the effect of cancer‐associated mutations on autocleavage. Mol Cancer 14: 33 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Villamil MA, Liang Q, Chen J, Choi YS, Hou S, Lee KH, Zhuang Z (2012) Serine phosphorylation is critical for the activation of ubiquitin‐specific protease 1 and its interaction with WD40‐repeat protein UAF1. Biochemistry 51: 9112–9113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yang K, Moldovan GL, Vinciguerra P, Murai J, Takeda S, D’Andrea AD (2011) Regulation of the Fanconi anemia pathway by a SUMO‐like delivery network. Genes Dev 25: 1847–1858 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Yin J, Schoeffler AJ, Wickliffe K, Newton K, Starovasnik MA, Dueber EC, Harris SF (2015) Structural insights into WD‐repeat 48 activation of ubiquitin‐specific protease 46. Structure 23: 2043–2054 [DOI] [PubMed] [Google Scholar]
  28. Yoder BL, Burgers PMJ (1991) Saccharomyces cerevisiae replication factor C: I. purification and characterization of its atpase activity. J Biol Chem 266: 22689–22697 [PubMed] [Google Scholar]
  29. Zhao G, Gleave ES, Lamers MH (2017) Single‐molecule studies contrast ordered DNA replication with stochastics translesion synthesis. Elife 6: e32177 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Expanded View Figures PDF

Source Data for Expanded View

Review Process File

Source Data for Figure 4

Data Availability Statement

This study includes no data deposited in external repositories.


Articles from EMBO Reports are provided here courtesy of Nature Publishing Group

RESOURCES